Clinical trials: Angle-Closure Glaucoma
- Condition Angle-Closure Glaucoma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Angle-closure Glaucoma
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma…
- Trial name
- NCT00762645
- Testing
- Travoprost 0.004% (Travatan), Pilocarpine 1%
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Intraocular Pressure
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily.
- Trial name
- NCT00758342
- Testing
- Travoprost 0.004% + Brinzolamide 1.0%, Travoprost 0.004% + Tears Natural
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Glaucoma, Angle-Closure
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
- Trial name
- NCT03362931
- Testing
- XEN45
- Where
- 16 sites in Australia, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Allergan
Glaucoma, Angle-Closure
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for…
- Trial name
- NCT01151904
- Testing
- brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, latanoprost
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- Allergan